Dear Editor,

We read with interest the article “Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism” recently published in this Journal (1).

The article was written by Brazilian endocrinologists and surgeons and consists of a consensus of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM). As a full version of it is also available in Portuguese language and free for download, it is definitely a valuable reference to Brazilian doctors in residency trainings and medical specialists in the fields of endocrinology, surgery, oncology and others.

Virtually all individuals carrying a germline mutation in the RET proto-oncogene will develop medullary thyroid carcinoma (MTC) and therefore total prophylactic thyroidectomy is indicated at early ages, based on the specific RET mutations (1-3).

In this context, we would like to make a comment regarding to the Y791F variant located at the exon 13 of RET. Although initial data regarding this variant indicated that it could be a weak mutation associated with mild forms of the disease (4,5), recent studies have shown no association of this variant with an increased susceptibility to MTC. Erlic and cols. (6) and Toledo and cols. (7) have analyzed the frequencies of RET Y791F in large cohorts of tumor free individuals and showed that the variant behaves as a rare non-pathogenic polymorphism rather than a disease-causing mutation. In addition, a thorough review of the literature does not document a link of Y791F (alone) with familial MTC. On the contrary, the reported Y791F carriers who inadvertently underwent thyroidectomy presented no histopathological signs of disease (5,6).

These data indicate that thyroidectomy should not be recommended to cases with genetic testing results showing RET Y791F (alone). However, especial attention should be taken by Brazilian doctors, geneticists and surgeons, as the RET Y791F variant has been identified in combination with the strong RET C634Y (exon 11) mutation in more than 15 Brazilian families with MTC/MEN2 (7,8). Noteworthy, this combination changes completely the clinical scenario, and patients with RET C634Y/Y791F should be treated accordingly to the recommendations to cases carrying RET C634 mutations, in which early total thyroidectomy is needed to be performed (1-3). Therefore, when receiving a genetic testing showing the presence of the RET Y791F variant, it is crucial to make sure that the remaining exons of the gene were completely sequenced as well, to fully certify whether is a Y791F-alone or a RET C634Y/Y791F patient (6).

In conclusion, we would like to congratulate the authors for the SBEM consensus and invite all the Brazilian medical doctors and geneticists to read our extended study and review of the literature about RET Y791F, a variant that need to be well understood by the health professionals of our country to the better management of Brazilian patients with MTC and their relatives (6).
Funding: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), grant number 401.990/2010-9 and the Fundação de Amparo à Pesquisa do Estado de São Paulo (Fapesp) grants number 2013/01476-9 (to Sergio P. A. Toledo) and 2006/60402-1 and 2010/51547-1 (to Rui M. B. Maciel). Rodrigo A. Toledo has received a Ciências Sem Fronteiras CNPq postdoctoral fellowship and is currently working at the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid. Sergio P. A. Toledo is a Senior Professor in the Division of Endocrinology, Department of Medicine, Federal University of São Paulo, SP, Brazil, with a grant from the Programa de Visitante Nacional Sênior – Edital 028/2013 – from the Coordenação de Aperfeiçoamentos de Pessoal de Nível Superior (Capes), Brazil.

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES